DENTSPLY SIRONA reports Q1 results on May 1 with the stock near multi-year lows, short sellers holding their largest position in months, and options traders buying downside protection at the most aggressive pace of the past year.
The options market is the clearest signal of how cautious the setup has become. The put/call ratio has climbed to 0.94 — more than two standard deviations above its 20-day average of 0.69 — making it the highest defensive reading of the past twelve months. That level has been building all week, rising from 0.74 on April 21 to 0.94 by the close on April 29. Traders are paying up for puts, and the pattern is unambiguous: the market wants insurance heading into Tuesday.
Short interest reinforces the picture, though the positioning here is more static than accelerating. Bears hold roughly 10.6% of the free float — a meaningful load, and a level that jumped sharply in mid-April when roughly 1.8 million additional shares appeared in the borrow market over just a few sessions around April 9-10. Since then, SI has plateaued in the 10.6-10.8% range rather than continuing to climb. The 30-day increase is still substantial at around 38%, but the weekly drift has turned fractionally lower, down about 1.3% over the past five days. The borrow market itself shows no sign of stress. Cost to borrow has nudged up 12% over the week to around 0.51%, still well inside one percent — a routine move, not a squeeze. Availability is loose relative to the short position, with the lending pool nowhere near exhausted. Bears are not being chased out, but they're also not pressing harder.
The Street is divided, and the recent Citigroup initiation sharpened the debate. Citi's Daniel Grosslight kicked off coverage on April 15 with a Sell rating and a $10 target — putting him below the current $11.48 close and well below the consensus cluster. Most of the rest of the covering analysts hold Neutral or equivalent ratings, with targets spread between $13 and $17 after a round of post-Q4 upward revisions in late February and early March. BofA Securities stands out as the lone upgrade, moving to Buy in February with a $17 target. The resulting consensus is a Hold, and the average target implies meaningful upside from here — but the Citi initiation signals that at least one bellwether firm sees the current price as fair value at best. Valuation multiples offer some context: PE sits at roughly 8x and EV/EBITDA around 7.3x, both modest levels that reflect the market's skepticism about whether the earnings base is reliable. The EV/EBITDA multiple has drifted slightly lower over the past 30 days, suggesting the discount is widening rather than closing.
The bull and bear cases are well-defined. Bulls point to positive Q4 momentum, progress on restructuring, and a decision to eliminate the dividend in favour of debt reduction and buybacks as signs that the new leadership is making the right calls. The 2026 financial outlook was characterised as strong after the February print, which produced a 14.7% one-day gain. Bears point to the same leadership backdrop from the other direction: repeated management changes, CFO turnover, a string of failed turnaround attempts, and no operational proof yet that the new plan will stick. The stock has lost 5.7% over the past week and closed at $11.48, essentially flat over the past month — the February spike has been fully given back. The March Q4 update produced a sharp -9.4% one-day move and a -12.8% five-day decline, a reminder that the stock reacts violently in both directions. Closest peer NVST was off 4.6% on the week, and ALGN fell 9% — the dental and medical device group broadly struggled, which provides some sector-level cover for XRAY's own weakness but makes it harder to attribute the move to stock-specific news.
Institutional ownership shows some fresh conviction on the long side: Southpoint Capital Advisors disclosed a new 10 million share position (5% of shares outstanding) as of March 11, the largest new institutional entry in the recent filings. Vanguard and BlackRock remain anchored at the top of the register near 11% and 9.4% respectively, both adding marginally in the March quarter. The chairman of the board, Greg Lucier, also bought 15,000 shares in early March at $12.45 — a small absolute dollar amount but notable given the level of executive scrutiny the company has attracted. Net insider activity over the prior 90 days was marginally positive in share terms, though largely offset by routine executive sales.
The May 1 print is the clearest near-term event to watch: whether the company can sustain the Q4 tone, what management says about the pace of operational recovery, and whether the Citi bear case — a stock already at $10 or below — finds any traction in the numbers.
See the live data behind this article on ORTEX.
Open XRAY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
